The common discussion of where to start a patients dosage of regorafenib. Steven J. Cohen, MD, the Chief of the Medical Oncology and Hematology Division at Jefferson Health/Abington Hospital and Vice-Chair of the Department of Medical Oncology at Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, talks with us about how he believes the ReDOS study is eye opening and how it helped patients in the long term.
Results of The ReDOS Study Affecting The Dosage of Stivarga (regorafenib) to Patients
